Huntingtin protein (HTT) lowering is a key therapeutic strategy for Huntington’s disease (HD). Reducing the amount of the disease-causing expanded HTT protein in the brain of patients is predicted to slow the progression of the disease. Several approaches are being employed to lower HTT including antisense oligonucleotides and siRNAs, as well as gene therapy approaches using viral delivery of miRNAs, shRNAs, and zinc-finger repressor proteins. Each of these potential therapeutic agents has inherent distribution challenges requiring direct delivery to the CNS. These challenges will be discussed as well as the pharmacodynamic biomarkers aimed to validate that delivery of a HTT lowering therapy does, in fact, lower the amount of HTT protein in the brains of HD patients.
- HTT lowering
- HTT protein
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.